Ganga Pharma.

Why is Ganga Pharmaceuticals Ltd falling/rising?

As of 18-Jul, Ganga Pharmaceuticals Ltd's stock price is stable at 12.00 with no recent changes, but it has increased by 2.74% year-to-date despite a 9.91% decline over the past year. The stock shows mixed performance across different time frames, with increased investor participation suggesting potential for future movements.

As of 18-Jul, Ganga Pharmaceuticals Ltd's stock price is currently stable at 12.00, showing no change (0.00%). Over the past week and month, the stock has not experienced any price movement, remaining at +0.00% for both periods. However, year-to-date, the stock has increased by 2.74%, contrasting with a significant decline of 8.30% in the Sensex during the same timeframe. <BR><BR>In the past year, the stock has decreased by 9.91%, while the Sensex has only fallen by 4.99%. Over a three-year period, Ganga Pharmaceuticals has shown a positive return of 15.38%, although this is lower than the Sensex's return of 17.36%. <BR><BR>Today's trading performance is described as inline with the sector, but there has been erratic trading, as the stock did not trade on 5 out of the last 20 days. The stock is currently trading higher than its 200-day moving average but lower than the 5-day, 20-day, 50-day, and 100-day moving averages. <BR><BR>There has been a notable increase in investor participation, with a delivery volume of 8,000 shares on January 22, which represents a 66.67% rise compared to the 5-day average delivery volume. This suggests a growing interest among investors, contributing to the stock's stability. Additionally, the stock is considered liquid enough for trading, based on its average traded value.<BR><BR>Overall, while Ganga Pharmaceuticals Ltd's stock price is currently stable, the mixed performance over different time frames and the recent increase in investor participation may indicate potential for future movements.

Which are the latest news on Ganga Pharma.?

What does Ganga Pharma. do?

Ganga Pharmaceuticals Ltd manufactures and trades Ayurvedic products and operates in the micro-cap market. As of September 2024, it reported net sales of 1 Cr and a market cap of INR 7 Cr.

Overview:<BR>Ganga Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceuticals and allied products, specifically in the Ayurveda sector, and operates within the micro-cap market.<BR><BR>History:<BR>The company was incorporated as a Public Limited Company in August 1994 and was promoted by Brij Mohan Sharma. In April 1995, Ganga Pharmaceuticals Ltd took over Ganga Pharmaceuticals, a proprietary concern that had been manufacturing and marketing Ayurvedic products for over two decades. The latest quarterly results reported net sales and net profit for September 2024.<BR><BR>Financial Snapshot:<BR>Net Sales: 1 Cr (Quarterly Results - Sep 2024) <BR>Net Profit: 0 Cr (Quarterly Results - Sep 2024) <BR>Market Cap: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 89.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.19 <BR>Return on Equity: 0.97% <BR>Price to Book: 0.86 <BR><BR>Contact Details:<BR>Address: Gangatat Dhanvantri Marg, Gopcharpada Virar (E) Palghar Maharashtra : 401305 <BR>Tel: 91-250-6098333/444 <BR>Email: ayurvedganga@gmail.com <BR>Website: http://www.ayurvedganga.com

How big is Ganga Pharma.?

As of 10th June, Ganga Pharmaceuticals Ltd has a market capitalization of 7.00 Cr, with net sales of 5.49 Cr and a net profit of 0.16 Cr reported in the latest four quarters. Shareholder's funds are 7.13 Cr, and total assets are valued at 8.97 Cr as of March 2025.

As of 10th June, Ganga Pharmaceuticals Ltd has a market capitalization of 7.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Ganga Pharmaceuticals reported Net Sales of 5.49 Cr and a Net Profit of 0.16 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amount to 7.13 Cr and Total Assets are valued at 8.97 Cr.

Who are in the management team of Ganga Pharma.?

The management team of Ganga Pharma includes Sanjay Vyankatesh Kulkarni (Chairman), Bharat Brijmohan Sharma (Managing Director & CEO), Srijna Sharma (Whole-time Director), and independent directors Sachin Chandrakant Chavan and Chetan Bhikhubhai Patel.

The management team of Ganga Pharma includes the following individuals:<BR><BR>1. **Sanjay Vyankatesh Kulkarni** - Chairman & Non-Executive Director<BR>2. **Bharat Brijmohan Sharma** - Managing Director & CEO<BR>3. **Srijna Sharma** - Whole-time Director<BR>4. **Sachin Chandrakant Chavan** - Independent Director<BR>5. **Chetan Bhikhubhai Patel** - Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Ganga Pharma.?

Ganga Pharma's peers include Beryl Drugs, Unjha Formulations, Vivanza Biosciences, Decipher Labs, Brawn Biotech, Shyama Computro, Fabino Enterprises, and Saroja Pharma. Most peers exhibit below-average management and capital structures, with Ganga Pharma showing an average capital structure and a 1-year return of -9.91%.

Peers: The peers of Ganga Pharma are Beryl Drugs, Unjha Formul., Vivanza Biosci., Decipher Labs, Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Beryl Drugs, Vivanza Biosci., Decipher Labs, Brawn Biotech, and Fabino Enter, while Average management risk is found at Unjha Formul. and Saroja Pharma In. Ganga Pharma has an Average capital structure, while Good capital structure is noted at Unjha Formul. The rest of the peers have Below Average capital structures, including Beryl Drugs, Vivanza Biosci., Decipher Labs, Brawn Biotech, and Fabino Enter. Growth ratings are Below Average for Beryl Drugs, Decipher Labs, Brawn Biotech, and Fabino Enter, while Average growth is seen at Vivanza Biosci. and Unjha Formul., and the rest do not qualify.<BR><BR>Return Snapshot: Beryl Drugs has the highest 1-year return at 31.73%, while Vivanza Biosci. has the lowest at -29.75%, with Ganga Pharma's 1-year return of -9.91% being better than Vivanza Biosci. but worse than Beryl Drugs. Additionally, the six-month return is negative for Vivanza Biosci., Decipher Labs, Brawn Biotech, and Fabino Enter.

When is the next results date for Ganga Pharmaceuticals Ltd?

The next results date for Ganga Pharmaceuticals Ltd is 21 May 2026.

The next results date for Ganga Pharmaceuticals Ltd is scheduled for 21 May 2026.

How has been the historical performance of Ganga Pharma.?

Ganga Pharma's historical performance shows stable share capital and a slight increase in reserves and shareholder's funds, with reduced long-term borrowings and improved total assets. Overall, the company reflects financial stability with low debt levels and positive cash flow from investing activities.

Answer:<BR>The historical performance of Ganga Pharma shows a consistent trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Ganga Pharma's share capital remained stable at Rs 4.84 crore from March 2024 to March 2025, while total reserves increased slightly from Rs 1.59 crore in March 2024 to Rs 1.67 crore in March 2025. Shareholder's funds also saw a modest rise, reaching Rs 7.13 crore in March 2025, up from Rs 7.05 crore the previous year. Long-term borrowings decreased from Rs 0.39 crore in March 2024 to Rs 0.23 crore in March 2025, indicating a reduction in debt levels. Total liabilities increased to Rs 8.97 crore in March 2025 from Rs 8.65 crore in March 2024, while total assets also rose to Rs 8.97 crore in March 2025 from Rs 8.65 crore in March 2024. The book value per share adjusted slightly to Rs 13.46 in March 2025 from Rs 13.30 in March 2024. Cash flow from operating activities remained at zero across the years, with cash flow from investing activities showing a positive inflow of Rs 1 crore in March 2025, contrasting with no activity in the previous year. Overall, Ganga Pharma's financial position reflects stability with slight improvements in reserves and assets, while maintaining low debt levels.

Has Ganga Pharma. declared dividend?

No Dividend History Available

Who are the top shareholders of the Ganga Pharma.?

The top shareholders of Ganga Pharma include Sharma Bharat B with 30.12%, Lenus Finvest Private Limited at 7.75%, and individual investors holding 35.07%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Ganga Pharma include the promoters, with Sharma Bharat B holding the largest share at 30.12%. The highest public shareholder is Lenus Finvest Private Limited, which owns 7.75%. Additionally, individual investors collectively hold 35.07% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.